Status:
UNKNOWN
ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features
Lead Sponsor:
Assiut University
Conditions:
Prostate Adenocarcinoma
Eligibility:
MALE
50-90 years
Brief Summary
Evaluation the ERG expression in prostatic acinar adenocarcinoma and its association with clinicopathological features.
Detailed Description
Prostatic cancer is one of the most common malignancies in males and is the second leading cause of cancer-related deaths in males worldwide. The burden is expected to grow 1.7 million new cases and 4...
Eligibility Criteria
Inclusion
- All cases diagnosed as prostatic acinar adenocarcinoma
Exclusion
- Other types of prostatic cancer.
Key Trial Info
Start Date :
May 4 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 23 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04825691
Start Date
May 4 2021
End Date
May 23 2023
Last Update
April 1 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.